Major Update: B2Broker Adds Match-Trader White Label
After integrating cTrader in 2022, B2Broker has continued to expand, with the integration of Match-Trader being the most recent. By adding Match-Trader, B2Broker, a worldwide provider of liquidity and technology for the FX and cryptocurrency markets, has announced the extension of its white label liquidity service. Thanks to this new integration, clients will have access to a full white label solution, highly competitive commercials, and a ready-made B2Core integration. This integration is a prime example of B2Broker's dedication to providing its clients with a complete and flexible service.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005066/en/
Match-Trader White Label Ecosystem (Graphic: Business Wire)
Match-Trader While Label Solution
To give brokers and their clients a complete Match-Trader experience, B2Broker has created a white label solution. The new service streamlines all necessary technologies into a single bundle to significantly reduce costs for brokers. The product includes:
- B2BinPay (a platform for processing cryptocurrency payments)
- B2Core (a CRM system)
- Access to B2Broker's Prime of Prime liquidity pool.
With all of these capabilities, the new Match Trader white label offering will surely be a hit in the brokerage sector.
The Match-Trader white label makes online trading easy with its wide range of features and services. This comprises round-the-clock server support and technical assistance, devoted account managers, and our knowledge to guide you through the brokerage environment. To make sure that your staff is completely up to speed with the new technology, training sessions are also offered as part of the white label package.
For companies wishing to take advantage of reduced trading fees and advantageous volume charges, the Match-Trader white label is the ideal option. Additionally, there are no setup fees, and the platform configuration is free. Customers simply need to deposit a minimum liquidity fee for three months as an initial investment. These clients receive a grace period of one full calendar month plus any leftover days since the terms of monthly minimum liquidity and connection were created, which makes it even more appealing.
Match-Trader x B2Core integration
B2Broker also empowers brokers with its Match-Trader and B2Core integration, allowing them to provide a seamless experience for their customers. Through the integrated trader's room, traders can easily open and manage accounts in real-time and connect directly to the platform. This new solution gives brokers access to a high-quality trading environment that rivals other popular platforms.
Creating a margin trading account with Match-Trader and B2Core became even easier. Start by creating a user account to link all your trading accounts. Once that's done, you can easily link your margin trading account with Match-Trader and start immediately. Trading with leverage has never been more accessible.
The B2Core team has added a new Match-Trader section to their Platforms tab, providing users with a range of features and capabilities. With the ability to create both demo and live accounts, users can test out different trading strategies in real-time. Furthermore, deposits, withdrawals, transfers, and internal transfers are all available within the platform. The dedicated Match-Trader terminal can be downloaded directly from the platform to make things even better. This is sure to open up a world of exciting opportunities for traders.
Verdict
The financial world is buzzing with excitement as the integration of B2Broker and Match-Trader brings a new level of robustness to brokers' online trading experience. Boasting user-friendly tools and features, this suite of technologies provides businesses access to advanced operations that keep them competitive in the market.
Furthermore, the upcoming integration of Match-Trader and IB programming will bring even more possibilities. This integration promises to provide users with an invaluable platform that caters to all types of businesses regardless of size or complexity.
Brokers will soon be able to offer a single platform with integrated Match-Trader and B2Core mobile, too, giving customers access to an array of features and capabilities. So don't miss out on this exciting product – keep an eye out for it in the near future!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005066/en/
Contact information
mail@b2broker.net
+44 208 068 8636
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom